Skip to Main Content

Browse issues

Volume 50, Issue 9, September 2020

Review

Satoru Taguchi and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 963–969, https://doi.org/10.1093/jjco/hyaa105

Radical prostatectomy and external beam radiotherapy are recognized as comparable treatment options for localized prostate cancer. This review summarizes the updated evidence on oncological outcomes of surgery versus radiotherapy.

Akira Kawai and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 970–975, https://doi.org/10.1093/jjco/hyaa121

This review covers the definition, epidemiology and therapeutic challenges of rare cancers and describes the establishment of the Rare Cancer Center at the National Cancer Center, Japan.

Shao-Yi Cheng and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 976–989, https://doi.org/10.1093/jjco/hyaa131

The advocacy of Advance Care Planning (ACP) is a means to honor patient autonomy. Since most East Asian countries are influenced by the Confucianism and the concept of ``filial piety'', patient autonomy is consequently subordinate to family values and physician authority. The dominance from family members and physicians during a patient's end-of-life decision-making is recognized as a cultural feature in Asia. In order to address this ethical and practical dilemma, the concept of `relational autonomy' and the collectivism paradigm might be ideally used to assist Asian people, especially older adults, to share their preferences on future care and decision-making on certain clinical situations with their families and important others. In this review article, we invited experts in end-of-life care from Hong Kong, Indonesia, Japan, South Korea, Singapore and Taiwan to briefly report the current status of ACP in each country from policy, legal and clinical perspectives.

Original Articles

Central Nervous System

Shigeko Umezaki and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 990–998, https://doi.org/10.1093/jjco/hyaa068

In addition to neurological deficits, symptoms were associated with poor QOL in patients with glioma. This study provided the basis on further investigation of usefulness of symptom evaluation on QOL improvement.

Nobuyoshi Sasaki and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 999–1008, https://doi.org/10.1093/jjco/hyaa073

In a retrospective analysis of newly diagnosed primary central nervous system lymphoma treated at a single institution, a higher complete response rate was observed in R-MPV in comparison with HD-MTX monotherapy. Furthermore, R-MPV followed by high-dose cytarabine consolidation seemingly bestowed longer survival.

Epidemiology/Public Health

Keiichi Shimatani and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1009–1017, https://doi.org/10.1093/jjco/hyaa083

This case-control study showed that cumulative tar exposure is a dose-dependent indicator for lung cancer risk, and low-tar exposure was still associated with increased cancer risk.

Head & Neck

Fumihiko Matsumoto and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1018–1022, https://doi.org/10.1093/jjco/hyaa079

Pull-through resection without reconstruction is more effective and less invasive than conventional open approaches for OPC and a particularly useful option in regions where TORS has not yet become widespread.

Immunology

Zhenyu Yang and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1023–1031, https://doi.org/10.1093/jjco/hyaa076

Our comprehensive meta-analysis of 6171 patients demonstrated that patients with higher tumour mutation burden were associated with a reduction of 43% risk of all-cause mortality and 50% risk of disease progression and a higher response rate.

Orthopedics/Sarcoma

Hiroshi Koike and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1032–1036, https://doi.org/10.1093/jjco/hyaa078

According to this systematic review, we weakly recommend that drug treatment can be performed irrespective of the tumour location in patients with extra-abdominal desmoid-type fibromatosis.

Tomohisa Sakai and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1037–1042, https://doi.org/10.1093/jjco/hyaa080

We performed a systematic review to verify the usefulness of CTNNB1 mutation analysis in the diagnosis of DF. It may be useful for the cases that have difficulty in histopathological diagnosis.

Atsushi Kagimoto and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1043–1050, https://doi.org/10.1093/jjco/hyaa084

Pulmonary emphysema with a GS of ≥5 points may be a factor that can influence the prognosis of patients with primary lung cancer.

Takahiro Mimae and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1051–1057, https://doi.org/10.1093/jjco/hyaa085

This study provides useful information with which to determine optimal surgical procedures for patients aged ≥80 years. Wedge resection might be an alternative to anatomical resection in such patients.

Tumor Markers

Ying Chen and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1058–1067, https://doi.org/10.1093/jjco/hyaa075

HAGLROS is a kind of long non-coding RNA. We found knockdown of HAGLROS in non-small cell lung cancer cells remarkably suppressed tumour proliferation, migration and invasion. Our results for the first time demonstrated HAGLROS may serve as a target for new therapies in non-small cell lung cancer.

Urology

Yoshiyuki Nagumo and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1068–1075, https://doi.org/10.1093/jjco/hyaa072

The prognoses of the patients with pure non-urothelial carcinoma of bladder were worse than those of the patients with pure UC.

Clinical Trial Note

Kiyo Tanaka and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1076–1079, https://doi.org/10.1093/jjco/hyaa092

A randomized phase III trial has started in order to confirm the clinical effectiveness of sublobar resection for early NSCLC with idiopathic pulmonary fibrosis comparing with lobectomy.

Cancer Genetics Report

Tetsuya Ito and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1080–1083, https://doi.org/10.1093/jjco/hyaa090

We report the first Japanese case of polymerase proofreading-associated polyposis carrying a POLD1 variant.

Image of the Month

Yusuke Otani and others
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1084–1085, https://doi.org/10.1093/jjco/hyz209

Cancer Statistics Digest

Matthew Palmer and Eiko Saito
Japanese Journal of Clinical Oncology, Volume 50, Issue 9, September 2020, Pages 1086–1087, https://doi.org/10.1093/jjco/hyaa148
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close